News & insights

Cambridge, UK – 23 April 2024: Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that Monument Therapeutics Limited (“Monument”) a precision neuroscience company spun-out from, and partly owned by Cambridge Cognition, has completed a £1.0 million fundraise and announced...

We caught up with the 2023 CANTAB Research Grant Secondary Award Winner, Louise Engelbrecht, who tells us how the grant will help to provide a better understanding of cognitive function during ultra-endurance performance and the role of ketone ester supplements to retain cognitive function. ​ I was elated when I...

Cambridge, UK – 10 April 2024: Cambridge Cognition, a leader in digital health solutions for brain health assessment, has announced the appointments of Alex Livingstone-Learmonth as Chief Commercial Officer and Annabelle Miles as Head of Marketing. These strategic additions mark a significant step as the Company continues strengthening its senior...

We caught up with the 2023 CANTAB™ Research Grant Secondary Award Winner, Eduardo López-Caneda, from the School of Psychology at the University of Minho​who. He shares with us how the grant will help to understand cognitive training and neuromodulation as a potential strategy to modify alcohol consumption habits. I am...

Cambridge, UK – 21 March 2024: Cambridge Cognition, a leader in digital health solutions for brain health assessment, announces the formation of a Scientific Advisory Board (SAB). This expert board will provide scientific guidance and valuable market insights, primarily focusing on addressing emerging trends such as the integration of blood-based...